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Summary 5-fluorouracil (5F-) is activated intracellularly to cytotoxic 5-fluoronucleotides (FNuct). These
were detected non-invasivelv in rats bearing the Walker carcinosarcoma bv 19F-magnetic resonance spectros-
copy (MRS) following an i.v. bolus dose of 5F (50 mg kg- ). Pre-treatment of the rats (3 to 24 h earlier) by
methotrexate (MTX) (20 or 50mg kg-') did not affect the rate of 5FU disappearance but did significantly
increase the rate of FNuct formation (P<0.002) and the final amount formed (P<0.02) as assessed by MRS
in vivo. MTX (20 mg kg-') caused substantially the same effects on FNuct formation (P<0.002 for rate and
P< 0.05 for the amount) when SFU was administered i.p. although higher doses of 5FC (120mg kg-') were
necessary to observe the '9F-signals. Quantitative analysis by MRS in vitro of extracts from the freeze-clamped
tumours treated by SFC i.v. confirmed that MTX pre-treatment increased FNuct formation 3-fold (P<0.05).
Hplc quantitative analysis demonstrated that 50Vo of the FNuct was the cytotoxic nucleotide FIJTP which was
also increased 3-fold in MTX treated animals (P<0.05). Since the Walker tumour is probably sensitive to
5FC action Via FITP incorporation into RNA. these results suggested that drug regimes in which MTX
preceded 5F1 (MTX-5F schedule) would be more cytotoxic that 5FU alone. At an MTX dose of
20 mg kg- 1 24 h prior to 5F11 there was significant inhibition of growth (P<0.05) compared to no treatment.
MTX alone or the reverse schedule of 5FU-MTX. These results suggest MRS may be of clinical value in
optimising chemotherapy using schedules where MTX precedes 5F.
The xenobiotic 5-fluorouracil (5FU) is used mainly in the
treatment of solid tumours such as colon, breast and head
and neck tumours (Grem, 1990). Although 5FU is the single
most active drug against colon cancer (Mackintosh et al.
1987) it is normally used in combination with other drugs,
particularly methotrexate (MTX). Preclinical studies estab-
lished that synergistic effects were obtained when MTX
preceded SFU (MTX-5FU schedules) although the optimal
scheduling of MTX-5FU combination chemotherapy appears
to vary from one experimental tumour type to another
(reviewed by Damon et al.. 1989). A recent report (Marsh et
al., 1991) demonstrated increased activity against advanced
colon cancer when MTX preceded SFU by 24 h rather than
1 h, but not for rectal cancer and thus a universal optimum
schedule has yet to be established in the clinic.
5FU cytotoxicity requires the anabolism of 5FU in
the tumour to 5-fluoronucleotides (FNuct), see Figure 1.
FNuct include (a) 5-fluoro-2'-deoxyuridine monophosphate
(FdUMP) which stops DNA synthesis by inhibition of
thymidylate synthase (TMPsyn), (b) 5-fluorouridine triphos-
phate (FUTP) which becomes incorporated into RNA,
interfering with RNA maturation and (c) 5-fluoro-2'-
deoxyuridine triphosphate (FdUTP) which can be mis-
incorporated into DNA (Pinedo & Peters, 1988). However,
FdUTP is probably removed from DNA by uracil-DNA
glycosylase and thus may not be important in 5FU cytotox-
icity (reviewed by Pinedo & Peters, 1988). These and other
fluoronucleotides may be detected non-invasively by the tech-
nique of '9F-nuclear magnetic resonance spectroscopy (19F-
MRS). In vitro the different nucleotides can be resolved
(Vialaneix et al., 1986), but in vivo they appear as a single
peak which also includes signals from FUMP, FUDP and
the FUDP-sugars; this FNuct peak remains clearly resolved
from the parent drug, the fluoro-catabolites or the 5-
fluoronucleosides (FNucs).
FNuct was first detected in vivo by '9F-MRS in the Lewis
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lung tumour in mice (Stevens et al.. 1984) and has subse-
quently been detected in numerous mouse and rat tumours
(reviewed by McSheehy & Griffiths. 1989) and more recently
in the liver metastases of patients (Semmier et al.. 1990). In
rats bearing the Walker carcinosarcoma (WK tumour) we
demonstrated that the intensity of this FNuct peak in vivo
could predict SFU toxicity towards that tumour. suggesting a
clinical role for '9F-MRS (McSheehy et al.. 1989).
MTX is a chemotherapeutic agent that does not require
metabolic activation to exert cytotoxic effects although they
are sustained by intracellular polyglutamation of MTX.
MTX causes inhibition of de novo purine synthesis through
depletion of intracellular reduced folates which causes a
rise in the cytoplasmic 5-phosphoribosyl-1-pyrophosphate
(PRPP) concentration (Damon et al.. 1989). In tumour cells
where SFU is activated via orotate phosphoribosyl trans-
ferase. increased PRPP results in greater conversion of 5FU
to FUMP and thus FNuct (Cadman et al.. 1981) (Figure 1).
Wayss et al. (1985) using the WK tumour grown s.c. in nude
Fl.rd - - FLUMP
tibose-1-
phosphate
PRPP
5F1.
FUDP -- FLTP -- FL-R\NA
FdlDP -_. FdUTP -- FL-DNA
deoxv-nbose
1-phosphate
FdLrd - FdULNP - FdUNIP-T TMPsvn-\THF
Figre 1 Cytotoxic anabolism of 5FC. Abbreviations are as
follows: 5-fluorouracil (5FU). 5-fluorounrdine (FUrd) and its 5'-
monophosphate (FUMP). diphosphate (FUDP) and triphosphate
(FUTP), 5-fluoro-2'-deoxyuridine (FdUrd) and its 5'-mono-
phosphate (FdUMP), diphosphate (FdUDP) and tnrphosphate
(FdUTP), 5FU incorporated into DNA (FU-DNA) and RNA
(FU-RNA), the FdUMP:thymidylate synthase:methylene-tetra-
hydrofolate covalent complex (FdUMP-TMPsyn-MTHF). 5-
phosphoribosyl-l-pyrophosphate (PRPP)-
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mice demonstrated that combination chemotherapy in which
MTX preceded 5FU increased cytotoxicity compared to
either drug alone or the reverse schedue of 5FU-MTX. In the
present study of tumours in rats we aimed to assess the
potential of MRS in vivo as a clinical aid in designing drug
regimes. Thus we determined (a) if '9F-MRS could detect
increased anabolism of 5FU to FNuct in the WK tumour
following pre-treatment with MTXh (b) if there was an
optimum time interval between the MTX and 5FU treatment
which maximised FNuct production in vivo, (c) if the com-
bination which produced most FNuct production led to in-
creased cytotoxicity and (d) the biochemical nature of the
components comprising the FNuct peak.
Methods
5FU and MTX were obtained from David Bull Laboratories
(Warwick. UK) and 5-fluorotryptophan was purchased from
Sigma Chemical Co. (Poole. Dorset. UK).
Tumours
Female Wistar rats (180-220g) were inoculated s.c. in the
flank with 2 x 10' Walker 256 carcinosarcoma cells (WK
cells) as previously described (McSheehy et al.. 1989). The
tumours were used for MRS studies when greater than 4 g
weight (calculated from (1 x w''2) (Klubes et al., 1978) where
length (1) and width (w) were measured with calipers), which
was normally 6-10 days after inoculation of the cells. The
same method was used for the tumour growth inhibition
studies. Rats were divided into groups of 10 and when the
group mean tumour weight was >4 g the rats were treated
i.p. as follows. Experiment (regimen) 1 (which used a 3 h
interval): 0.9% NaCl on day 5, or MTX (50mg kg-') fol-
lowed by 5FU (50 mg kg-') [MTX-5FU schedule], or the
reverse schedule [5FU-MTX]. Experiment (regimen) 2 (which
used a 24 h interval): 0.9% NaCl on days 6 and 7, or MTX
(20mg kg-') and 5FU (50mg kg-') on days 6 and 7 respec-
tively [MTX-5FU] schedule], or the reverse schedule [5FU-
MTX], or with a single dose of MTX alone on day 6.
Tumour size and body weight were always recorded daily.
'9F-MRS
All spectra were obtained at 75.5 MHz at room temperature
using a 1.9 T 30 cm horizontal-bore magnet (Oxford Re-
search Systems). Spectra (480 transients, spectral width of
4 kHz) were obtained in vivo using a 1.5 cm diameter 2-turn
surface coil with 14 ps radiofrequency pulses and a repetition
time (TR) of 1 s. With this coil a 90° ffip angle at the coil
centre corresponded to a 7 ps pulse.
Rats were anaesthetised with an i.p. injection of sodium
pentobarbitone (50 mg kg-1) before the jugular vein was can-
nulated. The surface coil was positioned centrally above the
tumour, and the magnetic field homogeneity was adjusted to
give a 'H signal linewidth of 0.24-0.6 p.p.m. (mean ± s.e. of
0.4 ± 0.1, n = 22). Thirty minutes after anaesthesia rats were
given a bolus injection (I ml in 0.5 min) of SFU (50 mg kg-')
through the jugular vein, and spectra were acquired immed-
iately in 8 min blocks for 67 min, at which point the tumours
were excised and freeze-clamped. The data analysis was as
previously described (McSheehy et al., 1989). Briefly, four
consecutive spectra collected over a period of about 33 mmn
were added, and the peak areas measured by the Oxford
Research Systems software. Thus the final time point of
experiments in vivo was at 33-67 min (mean of 50 min).
while for analysis in vitro it was 67 min, the time of freeze-
clamping. All chemical shifts were referenced to 5FU (O
p.p.m.). Animals that had first received MTX (20 or
50 mg kg-') were treated exactly as described above. MTX
was administered as an i.p. bolus injection 3, 6, 12 or 24 h
prior to the SFU injection.
MRS studies were also made following the injection of
5FU i.p. (120 mg kg-'). Since positioning of the animal and
shimming took about 15 min following the i.p. injection.
spectra began in blocks (9 x 8 min) at 14 min post 5FU and
continued up to 87 min to allow for the slower appearance of
FNuct. The mean ± s.e. linewidth of the 'H peak was
0.56 ± 0.15 p.p.m. (n =8). Spectra in vivo were analysed as
described above so the final time point for i.p. injection was
54-87 min (mean of 71 min). When administered, MTX was
given 24 h earlier at 20 mg kg-' i.p.
Acid extracts and hplc
Tumour extracts were made (2.5g from each tissue) using
10 ml of cold 6% (v v) perchlonrc acid and were neutralised
with KOH. The extracts were freeze-dried and concentrated
to a 2.5 ml solution. Aliquots (200p1) were stored at - 20'C
for hplc and the remainder analysed by MRS. Spectra
(6-7000 transients with a spectral width of 6 or 8 kHz) were
obtained in vitro using a solenoid coil with 9p.sec pulses (flip
angle = 90°) and a TR of 8.5 s from a 2 ml solution contain-
ing 200 nmoles of 5 fluorotryptophan as a standard for quan-
titation and chemical shift reference. Ion-exchange hplc was
performed on diluted samples as previously described (Mc-
Sheehy et al.. 1989) using the method of Prior. (1990) which
had a sensitivity limit of 0.5-1 nmoles (0.01-0.02 mM).
Statistics
Student's t-test was used except where three or more groups
were compared. when Gabriel's one-way analysis of variance
was used (Kendall & Stuart. 1968). Rates of formation or
disappearance were generated by linear regression of the
FNuct values or log values for SFU to determine a t4 value
for 5FU.
Results
A single i.v. bolus dose of 5FU (50 mg,kg) produced
sufficient 5FU in the WK tumour to observe anabolism to
FNuct (Figure 2b). FNucs or catabolites of 5FU such as
m-fluoro-p-alanine (FBal) and a-fluoroureidopoprionic acid
(FUPA) were not visible in vivo at these doses. FNuct in-
creased with time at a rate which appeared to exhibit zero-
order kinetics, while the 5FU signal decreased exponentially
until 50 min when the areas of the peaks were similar. Pre-
treatment of the animal with MTX using either a regimen of
50 mg kg-' 3 h prior to 5FU (regimen 1) or 20 mg kg-' 24 h
prior to 5FU (regimen 2) caused a faster rate of FNuct
formation resulting in an increased peak area after 50mmn
(Figure 2a). These two patterns of metabolism were repro-
ducible and the results from twelve animals are summarised
in Figure 3. Where animals were pretreated with either
regimen of MTX, formation of FNuct reached a maximum
before the end of the experiment (at around 40 min), whereas
the 5FU signal declined during 50 min in a manner similar to
that of the controls. 5FU disappearance exhibited first-order
kinetics, enabling the calculation of a t1 of around 17 min
which clearly was unaltered by regimens 1 or 2. In contrast
the rate of FNuct formation was significantly increased about
3-fold (P<0.002) (Table I). Using an MTX dose of
20 mg kg-' i.p. three other time intervals of 3, 6 or 12 h prior
to 5FU administration were investigated. These produced
very similar patterns of metabolism to those shown in Figure
3 (data not shown).
When 5FU was injected at the same 50 mg kg-' dose but
i.p. instead of i.v., '9F signals were not visible at the field
strength of 1.9 T although we have subsequently found that
5FU, FNuct and FPia can be observed at 4.7 T from a
similar dose (results not shown). At a dose of 120 mg kg-'
i.p. 5FU was always visible and in 3 of4 tumours FNuct was
seen 30 min after injection and then increased at a rate
similar to that following the 50 mg kg-' i.v. dose (Figure 4a,
Table I). Pre-treatment 24 h earlier by MTX (20 mg kg ')
did not alter the amount of SFU in the tumour, but did
slightly increase the ti (P<0.05) and more importantly in-'9F-MRS OF MTX-5FU COMBINATION CHEMOTHERAPY 371
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Figre 2 9F-MRS spectra in vivo
of 5FU metabolism 'th
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pre-treatment. Rats recived
ant i.v. bolus injection of 5FU (50mg kg-') at zero time and data acquisition began immediately and continued for 67 min. The
spectral width was 4 KHz and a TR of 1 s was used. Results show the final time point (50 mmn) from 1920 1 s transients in a
tumour that had been treated with MTX (50 mg kg-' i.p.) 3 h prior to 5FU a, and a tumour receiving no pre-treatment b.
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Figue 3 5FU injected iv.: peak integrals of 5FU and FNuct
from MRS spectra in vivo following 5FU or MTX-5FU treat-
ment. Rats received an i.v. bolus injection of 5FU (50mg kg-')
at zero time. The data are from summed spectra as described in
Methods. Results show the mean ± s.e. of the 5FU (0) and
FNuct (-) peak areas from four separate experiments for each
different treatment schedule (ab, or c.) a, 5FU alone, b, MTX
(50 mg kg-' i.p.) 3 h prior to 5FU. c, MTX (20 mg kg-' i.p.) 24 h
prior to 5FU.
Table I Kinetics of 5FU disappearance and FNuct formation in the
WK tumour in vivo
Treatment (mgkg-') 5Fl t, in minutes FNuct line slope
(50) 5FU i.v. 17.4 0.9 r = 0.99 1.73 0.29 r = 0.96
(50) MTX 3 h 16.5 1.9 r= 0.98 5.66 +0.6' r= 0.99
(50) 5FU i.v.
(20) MTX 24 h 16.3 1.1 r = 0.99 5.39+0.2' r = 0.99
(50) 5FU i.V.
(120) 5FU i.p. 36.6 3.0 r = 0.99 1.40 0.14 r=0.98
(20) MTX 24 h 57.6 5.5 r = 0.98 4.46 0.16 r=0.99
(120) 5FU i.p.
Results show the mean ± s.e. of data calculated from the graphs
shown in Figures 3 and 4. 'P<0.002 when compared with the 5FU
alone dose using Gabriels one-way analysis ofvariance. Columns two
and three also show the value of the correlation coefficient r.
creased by about 3-fold the rate of FNuct formation
(P<0.002) and the final amount of FNuct (P<0.05) (Figure
4B, Table I).
Tumour extracts from animals treated by 5FU i.v. were
analysed quantitatively bv MRS in vitro. This analysis
confirmed that FNuct was increased 2-3 fold when rats were
pre-treated with MTX. while less of the parent drug was
visible compared to extracts from controls (Figure 5). Signals
corresponding to the catabolites, particularly FBal. were visi-
ble in vitro and were generally slightly increased, but not
significantly so. in MTX-treated animals. A summary of the
extract analysis and observations in vivo is shown in Table II,
the data are from the same tumours shown in the time
courses in Figure 3. Extracts were also analysed by ion-
exchange hplc to determine the proportions of the different
nucleotides in the FNuct peak. The largest contribution was
from the cytotoxic nucleotide FUTP which constituted about
50% of the total FNuct signal and was increased 3-fold in
MTX-treated animals. Values for the other two potentially
cytotoxic nucleotides FdUMP and FdUTP could not be
determined because they could not be resolved from the
ribonucleotides by this method.
Growth inhibition
Klubes et al. (1978) demonstrated that a single high dose of
5FU (120 mg kg-') did not alter growth of the WK tumour.
In our preliminary studies investigating 5FU and MTX com-
bination chemotherapy on this tumour, we also found that
growth following a single dose of 5FU (50 mg kg-') was
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Fiure 4 5FU injected i.p.: peak integrals of 5FU and FNuct
from MRS spectra in vivo following 5FU or 5FU-MTX treat-
ment. Rats received an i.p. bolus injection of 5FU (120 mg kg-l)
at zero time and data acquisition began after 14min and con-
tinued for 87 min. The data are from summed spectra as des-
cribed in Methods. Results show the mean ± s.e. of the 5FU (0)
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indistinguishable from controls. while a single dose of MTX
(50 mg kg-') did significantly reduce growth (results not
shown). Indeed. 50 mg kg-' 5FU daily for one week is neces-
sary to significantly inhibit growth of the WK tumour when
5FU is the sole of chemotherapeutic agent (McSheehy et al..
1989). A preliminary experiment is presented in Figure 6a
which shows the effect of combining MTX and 5FU using
the dose regimen 1 (see Methods). This combination com-
pletely arrested growth. although the MTX-5FU schedule
was no more effective than the reverse schedule of 5FU-
MIX. Both these schedules with higher doses of MTX were
fairly toxic causing up to 10% body weight loss relative to
controls, the MTX-5FU schedule being the more toxic (Table
III). When the MTX dose was reduced to 20 mg kg' and
the interval between treatments was extended (regimen 2)
there was a significant difference in cytotoxicity between the
MTX-5FU and 5FU-MTX treatment schedules (Figure 6b).
The MTX-5FU schedule was the most cytotoxic and was
indeed the only schedule to cause a cessation of growth.
There was again significant body weight loss relative to
controls which was once more least in the 5FU-MTX
schedule and similarly high in the MTX alone and MTX-
5FU schedules (Table III).
Diusswio
We (McSheehy et al., 1989) and others (El-Tahtawy et al..
1989) have already demonstrated that FNuct is readily
formed from 5FU in the WK tumour at concentrations
visible by 9F-MRS in vivo. Here, we have administered 5FU
i.v. at a dose of 50 mg kg-' which is similar to doses received
by patients in the clinic (in g m-2). Our previous study using
this same tumour model showed that the level of FNuct
formed in vivo was pertinent in predicting cytotoxicity (Mc-
Figure 5 '9F-MRS spectra of extracts from WK tumours treated
with MTX and 5FU a. or 5FU alone b. Extracts were made from
tumours freeze-clamped 67 min after treatment with 5FU (50
mg kg-' i.v.) with a. or without b. MTX pre-treatment. Results
shown are from the two experiments shown in Figure 2. The
spectral widths were 8 kHz a. and 6 kHz b. each spectrum
obtained from 6500 transients using a TR of 8.5 s. FTrypt:
200 nmoles 5-fluorotry-ptophan.
Table II Summary of 5FU metabolism by WK tumour following
injection of 5FU i.v-. with and without MTX pre-treatment:
observations in vivo and quantitation in vitro
Treatment Peak Integrals Concentrations in extracts
schedule in vivo (nmoles g- tissue)
(mgkg-' 5FU FVuct 5FU FNuct Catabs FL'TP
5FUalone 105± 13 84±20 32±6 73±20 9± 2 31 ± 15
(50) MTX 100 ± 17 231 ± 56a 11 ± 9 199 ± 14b 15 + 9 108 ± 24b
3 h 5FU
(20) MTX 73 ± 17 243 ± 34 21 6 156 ± 17b35 ± 12 93 ± ll
24 h 5FU
Samples are the same as those shown in Figure 3. Results in vivo show
the final time-point (50 min) in arbitrary units while in vitro the final
time-point was 67 min. All values are the mean ± s.e. of four tumours
for each different treatment schedule, where treatment with 5FU was
always 50kg kg-' i.v. and pre-treatment with MTX (i.p.) was either
50mgkg-' 3h pnror to 5FU or 20 mg kg- 24 h prior to 5FU.
Quantitation of the extracts was by MRS in vitro and hplc. 'P<0.02.
bp<0.05, when compared to 5FU alone using Gabnrel's one-way
analysis of variance.
Sheehy et al.. 1989). Analysis of the FNuct in those tumour
extracts showed that changes in FNuct were complementary
with changes in the cytotoxic nucleotide FUTP, which comp-
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Figure 6 Inhibition of WK tumour grow
and 5FU treatment schedules. Tumours
weight measured as described in Methods.
were as follows: a. (3 h interval): 0.90o ?
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mean ± s.e. from ten animals in each gro
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the [MTX] and [5FU-MTX] scheduling usi
analysis of variance.
FUTP concentrations have been linked
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1979: Benz & Cadman. 1981: Cadman et
& Griffiths, 1991). Furthermore. althou
forms up to a maximum of 5 nmoles-' o
of a 120mg kg-' bolus dose of 5FU. ti
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large endogenous pool of dUMP whicl
FdUMP for TMPsyn and (b) rapid cleai
(Klubes et al.. 1978). Thus incorporation
is probably the major mechanism of SF1
tumour.
If FUTP incorporation into RNA M
dominant mechanism of cytotoxicity in
combination chemotherapy designed to
towards FUTP formation should increas
has been used successfully in viio, in
clinical situations to increase 5FU cytot(
tic manner when administered prior tc
Damon et al., 1989). This effect is prob
increase in intracellular levels of PRPI
been demonstrated in many cell lines (Be
Cadman et al.. 1981: Benz et al.. 1982)
(Houghton et al.. 1982).
In this report we have shown in vivo ti
MTX from 3 to 24 h prior to the injectio
a very rapid formation of FNuct so th,
administration there was a 3-fold incre
a Table 111 Toxicity of the different treatment schedules as assessed by
the mean change in rat body weight
Treatment B-odiweight fg) % Change in
schedule Da! 0 Da! 3 weight
Control(l) 224± 2 214± 4 -4.1 + 1.5
5FU 3 h MTX 222 ± 3 207 ± 4 -6.7± 1.3
MTX3h5FU 222±3 204± 7 -9.7+1.6a
Control(2) 225 ± 7 227 ± 8 +0.9 ± 1.1
MTX alone 226 ±7 210 ± 8 -9-3+ 21
5FU 24hMTX 228±6 220± 6 -3.4± 1.3
MTX 24h 5FU 219 ±9 197 ± 11 -8.8 ± 2,4b
Results are from two different experiments (1 and 2). where day 0 is
9 10 11 the first day oftreatment. The methods and scheduling ofthe treatments
are as described in Methods. Values shown are the mean ± s.e. of10 rats
for each schedule. ap <0.05 when compared to control(1) and bp < 0,05
b when compared to control(2) and the 5FU-MTX schedule using
Gabnrel's one-way analysis of vanrance.
7
compared to tumours treated with 5FU alone (Figure 3). A
very similar effect. but beginning later following injection.
0 + could be seen when 5FU was administered i.p. (Figure 4). A
-0 1 higher dose of 5FU was necessary in order to make the MRS
-7 7 b observations after i.p. administration compared with i.v.
b administration. and this doubled the t4 for 5FU disap-
pearance possibly due to a continuous supply of 5FU from
the blood as anabolism in the tumour proceeded (Table I).
9 10 11 Catabolism of 5FU is probably not significant in this tumour
(see below). However, it seemed clear that once 5FU entered
the tumour FNuct was formed at a rate that was indepen-
-th bv different MTX dent of the dose or mode of administration. Furthermore. the
*ere initiated and the effect of MTX was always to increase the rate of formation
Treatments (all i.p.) of FNuct about 3-fold (Table I). It is interesting to note the
NaCl 0 [Control(1)]. t, value for 5FU disappearance in the tumour was con-
)mgkg-') V [MTX- sistently found to be around 17 mn when 50 mg kg-' 5FU
NX. b. (24 h interval): was administered i.v. (Table I). In the liver of these rats
s')followed by 5FU following a similar dose of 5FU (60mg kg-' i.v.) the t- was e sechedule A [5FU-
FX]. Results show the found to be 5 min (Prior et al.. 1990). suggesting that 5FU is
)up 'P<0.0001 com- likely to persist in non-hepatic tissues.
red to control(2) and The effect of MTX to increase the rate of FNuct formation
Ing Gabnel's one-way appeared to be independent of the time intervals (3. 6. 12 or
24 h) that we used. Other investigators using cell lines in *itro
(Benz & Cadman. 1981. Benz et al.. 1982) or tumours grown
in vivo (Brown & Ward, 1978: Herrmann et al.. 1985) have
found the length of time by which MTX precedes 5FU to be
to increased cvtotox- important for obtaining maximum 5FU activation. The fact
& Handschumacher. that 5FU activation was unchanged in our different schedules
al.. 1981: McSheehv suggests there may be significant polyglutamation of MTX
gh the WK tumour by the WK cells. thus preventing MTX efflux and so sustain-
f FdUMP within 2 h ing intracellular MTX levels.
his has proved to be The analysis of the tumour extracts by MRS in vitro
probably to (a) the confimed the observations in vivo except that low levels of
h competes with the 5FU-catabolites could also be detected (Table IIL Figure 5).
rance of the FdUMP We have found that the catabolites are rarely visible in rat
of FUTP into RNA tumours in vivo during the first 60 min of 5FU metabolism
U cytotoxicity in this (McSheehy et al., 1989: Prior et al.. 1990) probably because
the levels were simply below the detection limit in isvo.
vere indeed the pre- Anyway. the catabolites probably owe their origin to re-
WK tumours then circulation from the liver since we have found that isolated
increase anabolism WK cells do not catabolise 5FU (unpublished observations).
se cytotoxicity. MTX As we have previously observed in this tumour. signals cor-
vitro and in some responding to the FNucs were never seen in vivo or in vitro.
oxicitv in a synergis- Hplc analysis of the same extracts confirmed earlier observa-
5FU (reviewed by tions in the WK tumour (McSheehy et al.. 1989) that 50%0 or
bably mediated by an more of the acid-extractable FNuct was FUTP. This propor-
? (Figure 1), as has tion was unchanged in MTX-treated animals although the
nz & Cadman. 1981: final concentration (nmoles g-i) was three times that of con-
and some xenografts trols (Table II). Thus this result was consistent with MTX-
pretreatment causing an increase in tumour levels of PRPP
hat administration of leading to increased metabolism of 5FU to FUMP and
)n of 5FU i.v. caused subsequently FUTP (Figure 1).
at 50 min after SFU Since FUTP levels were so markedly increased. was 5FU
!ase in FNuct levels cytotoxicity in the WK tumour increased? Our observations
I
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(see also McSheehy et al.. 1989) confirm those of Klubes et
al. (1978) that the WK tumour is relatively unresponsive to
5FU. However. when in combination with MTX. growth was
arrested by 5FU (Figure 6). Clearly the WK tumour was
very sensitive to MTX since even a single low dose (20
mg kg-') inhibited growth (P = 0.05 in a simple t-test when
comparing the growth rates of control (2) and MTX alone
groups in Figure 6b). This high sensitivity of the WK tumour
to MTX explained the absence of a difference between the
5FU-MTX and MTX-5FU schedules in the preliminary ex-
periment where a higher MTX dose (50 mg kg-') was used in
combination with a single dose of 5FU alone that was
known not to affect growth at all (Figure 6a). However, in
regimen 2 when the MTX dose was 20 mg kg-' the MTX-
5FU schedule was the only one that caused significant inhibi-
tion of tumour growth (Figure 6b). In any event, a higher
FNuct formation in viivo predicted increased cytotoxicity
when MTX preceded 5FU as opposed to a dose of 5FU
alone. We were unable to detect '9F-signals 3 or 24 h after
injection of 50mgkg-1 5FU i.v. whether MTX was admin-
istered or not.
Combination chemotherapy where MTX precedes 5FU
causes toxicity in gastrointestinal tissue rather than bone-
marow (see for example Houghton et al.. 1982 and reviewed
by Damon et al.. 1989). Thus a change in body weight is a
valid parameter by which to assess toxicity. Relative to con-
trols the toxicity of the MTX-5FU regimes. although
significant. was not excessive (Table III). However, when
5FU preceded MTX (reverse schedule) there was both less
cytotoxicity (Figure 6b) and less general toxicity compared to
the MTX alone or MTX-5FU schedule (Table III). This type
of effect is not surprising since 5FU can antagonise the
anti-purine effect of MTX (Grem. 1990).
Hufl et al. (1988) made a '9F study of 5FU metabolites in
the plasma and urine of patients receiving 5FU or MTX-
5FU chemotherapy. No differences could be detected in the
levels of 5FU metabolites in patients receiving the mono or
combination chemotherapy or in responders or non-respon-
ders. suggesting that studies of tumour tissue were necessary
to detect individual responsiveness to 5FU. We have pre-
viously demonstrated that WK tumour FNuct levels that are
MRS-visible were pertinent in predicting 5FU cytotoxicity
(McSheehy et al.. 1989). This observation has now been
extended to Ehrlich ascites tumour cells (McSheehy &
Griffiths. 1991) and also RIF-1 tumours (Sijiens et al.. 1991).
Koutcher et al. (1987) using the CD8Fl murine mammary
tumour showed pre-treatment of mice with MTX also in-
creased the MRS-visible FNuct. Our results presented here
have used a tumour that readily metabolises 5FU to FUTP
and is probably sensitive to 5FU via RNA-directed cytotox-
icity. Pre-treatment of tumour cells with MTX can increase
this effect and we have shown that this can be predicted by
MRS in vivo using the WK tumour.
There remains much clinical interest in optimising the time
interval in schedules where MTX precedes 5FU. many of
which include folinic acid rescue to ameliorate host toxicity.
Our results here suggest that '9F-MRS might be of value in
developing these drug regimes.
This work was supported by the Cancer Research Campaign. UK.
Preliminary findings were first reported at the 30th annual meeting
of the Bnrtish Association Cancer Research (1989).
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